Equities Analysts Issue Forecasts for DAWN Q1 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Day One Biopharmaceuticals in a note issued to investors on Thursday, October 31st. HC Wainwright analyst A. Maldonado expects that the company will earn ($0.34) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals' Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.20) EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million for the quarter, compared to the consensus estimate of $15.05 million. During the same period in the previous year, the firm earned ($0.54) EPS.

A number of other analysts also recently commented on the stock. Bank of America upgraded shares of Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and boosted their price target for the stock from $11.00 to $24.00 in a research report on Thursday, August 1st. Piper Sandler restated an "overweight" rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Needham & Company LLC reiterated a "buy" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday. Wedbush reissued an "outperform" rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Finally, JPMorgan Chase & Co. lowered their target price on Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a report on Tuesday, August 6th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Day One Biopharmaceuticals has an average rating of "Moderate Buy" and an average price target of $35.71.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN traded up $0.16 during midday trading on Monday, reaching $14.81. 1,354,722 shares of the company traded hands, compared to its average volume of 939,181. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -14.22 and a beta of -1.51. The stock has a 50-day moving average price of $14.19 and a 200 day moving average price of $14.39. Day One Biopharmaceuticals has a 52 week low of $10.90 and a 52 week high of $18.07.

Insider Transactions at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 3,202 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the transaction, the general counsel now owns 26,928 shares in the company, valued at $376,992. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,232 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares in the company, valued at approximately $15,785,490. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the transaction, the general counsel now owns 26,928 shares in the company, valued at $376,992. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 48,748 shares of company stock valued at $689,072 over the last three months. Company insiders own 8.40% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

Several institutional investors have recently made changes to their positions in DAWN. Mirae Asset Global Investments Co. Ltd. lifted its position in Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock worth $51,000 after buying an additional 1,002 shares in the last quarter. SG Americas Securities LLC acquired a new position in Day One Biopharmaceuticals in the 2nd quarter worth about $113,000. Point72 DIFC Ltd acquired a new position in Day One Biopharmaceuticals in the 2nd quarter worth about $124,000. Hsbc Holdings PLC purchased a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth about $163,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Day One Biopharmaceuticals during the 1st quarter valued at about $221,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.